
BioLife Solutions downgraded to Hold amid $1.5B Repligen acquisition and shareholder fairness probe
BioLife Solutions stock was downgraded to a 'Hold' rating with a $31 price target by Lake Street amid its proposed $1.5 billion acquisition by Repligen Corporation. The deal, a cash-and-stock offer, is under legal scrutiny by Halper Sadeh LLC, which ...



